A Study of KRN23 in X-linked Hypophosphatemia
Status: | Archived |
---|---|
Conditions: | Other Indications, Metabolic |
Therapuetic Areas: | Pharmacology / Toxicology, Other |
Healthy: | No |
Age Range: | Any |
Updated: | 7/1/2011 |
Start Date: | December 2008 |
End Date: | July 2011 |
A Phase I, Double-blind, Randomized, Placebo-controlled, Single-dose, Dose-escalation Study of KRN23 in X-linked Hypophosphatemia
The primary objective of this study is to assess the safety and tolerability of KRN23 after
a single intravenous (IV) and subcutaneous (SC) administration in XLH patients.
We found this trial at
4
sites
Yale University School of Medicine Founded in 1810, the Yale School of Medicine is a...
Click here to add this to my saved trials
7000 Fannin St
Houston, Texas 77030
Houston, Texas 77030
(713) 500-4472
University of Texas Health Science Center at Houston The University of Texas Health Science Center...
Click here to add this to my saved trials
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
Click here to add this to my saved trials